Novel p-oxybenzoic acid derivatives, processes for their production and
申请人:Klinge Pharma GmbH
公开号:US04582857A1
公开(公告)日:1986-04-15
P-oxybenzoic acid derivatives of formula (1) ##STR1## wherein R.sup.1 is hydrogen, or straight or branched alkyl of one to four carbon atoms; n is 1 or 2; X is ##STR2## and R.sup.2 is --OH or --NHCH.sub.2 COOH; and non-toxic pharmaceutically acceptable salts thereof. The compounds exhibit a hypolipemic effect. They may be prepared by methods known in themselves from the corresponding ester or acid halide compounds, wherein optionally the secondary alcohol group may be oxidized to a keto group.
Process for preparing the pure enantiomers of lifibrol and its alkyl
申请人:Klinge Pharma GmbH
公开号:US05266721A1
公开(公告)日:1993-11-30
The preparation of the pure enantiomers of LIFIBROL and its alkyl esters is achieved with surprisingly good yield by reacting the pure enantiomeric forms of S(-) R(+)-4-(4-tert.butylphenyl)-1,2-epoxy butane with 4-hydroxybenzoic acid alkyl ester at elevated temperature in DMF and in the presence of 4-hydroxybenzoic acid alkyl ester sodium salt. Thereafter, the raw reaction product is separated. Either the stereochemically pure LIFIBROL ester is then recovered by recrystallization or the precipitated LIFIBROL enantiomer is made in pure crystalline form by mild alkaline saponification and subsequent acidification.
Neue p-Oxibenzoesäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
申请人:Klinge Pharma GmbH
公开号:EP0481253A2
公开(公告)日:1992-04-22
p-Oxibenzoesäurederivate der allgemeinen Formel (1)
in der bedeuten:
bedeutet, ihre physiologisch verträglichen Salze sowie ihre enantiomeren als auch diastereomeren Formen besitzen hypolipämische Eigenschaften und eignen sich daher zur Herstellung von Arzneimitteln mit hypolipämischer Wirkung.